THIRD QUARTER HIGHLIGHTS Production and Fourth Quarter Expectations: The Company produced 87,020 ounces of gold in the third quarter, in line with expectations and operating plans, which fully support ...

TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...

Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% ...

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...

Researchers set a new world record for the fastest DNA sequencing, completing a whole genome in under four hours—a ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Q3 2025 Management View CEO Jacob Thaysen reported, "In the third quarter, we delivered another strong performance with ...